Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily J Lelliott

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
NPJ Precision Oncology|April 21, 2022
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?Emily J Lelliott, Karen E Sheppard, Grant A McArthur
Frontiers in Immunology|May 24, 2021
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of MelanomaEmily J Lelliott, Grant A McArthur, Jane Oliaro, et al.
Cancers|June 19, 2020
Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?Lorey K Smith, Shaghayegh Arabi, Emily J Lelliott, et al.
Frontiers in Immunology|July 25, 2022
NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit InflammationEmily J Lelliott, Kelly M Ramsbottom, Mark R Dowling, et al.
Science Advances|February 20, 2021
SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cellsConor J Kearney, Stephin J Vervoort, Kelly M Ramsbottom, et al.
Cancer Immunology Research|January 18, 2019
Antagonism of IAPs Enhances CAR T-cell EfficacyJessica Michie, Paul A Beavis, Andrew J Freeman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2026
CDK4/6 Inhibition Enhances CAR-T Cell Therapy in Solid TumorsEmily J Lelliott, Jonathan Naddaf, Kun-Hui Lu, et al.
International Journal of Cancer|December 16, 2017
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceClaire A Martin, Carleen Cullinane, Laura Kirby, et al.
Scientific Reports|February 6, 2019
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapyEmily J Lelliott, Carleen Cullinane, Claire A Martin, et al.
Cell Death and Differentiation|September 11, 2024
Intracellular zinc protects tumours from T cell-mediated cytotoxicityEmily J Lelliott, Jonathan Naddaf, Katherine Ganio, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
NPJ Precision Oncology|April 21, 2022
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?Emily J Lelliott, Karen E Sheppard, Grant A McArthur
Frontiers in Immunology|May 24, 2021
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of MelanomaEmily J Lelliott, Grant A McArthur, Jane Oliaro, et al.
Cancers|June 19, 2020
Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?Lorey K Smith, Shaghayegh Arabi, Emily J Lelliott, et al.
Frontiers in Immunology|July 25, 2022
NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit InflammationEmily J Lelliott, Kelly M Ramsbottom, Mark R Dowling, et al.
Science Advances|February 20, 2021
SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cellsConor J Kearney, Stephin J Vervoort, Kelly M Ramsbottom, et al.
Cancer Immunology Research|January 18, 2019
Antagonism of IAPs Enhances CAR T-cell EfficacyJessica Michie, Paul A Beavis, Andrew J Freeman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2026
CDK4/6 Inhibition Enhances CAR-T Cell Therapy in Solid TumorsEmily J Lelliott, Jonathan Naddaf, Kun-Hui Lu, et al.
International Journal of Cancer|December 16, 2017
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceClaire A Martin, Carleen Cullinane, Laura Kirby, et al.
Scientific Reports|February 6, 2019
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapyEmily J Lelliott, Carleen Cullinane, Claire A Martin, et al.
Cell Death and Differentiation|September 11, 2024
Intracellular zinc protects tumours from T cell-mediated cytotoxicityEmily J Lelliott, Jonathan Naddaf, Katherine Ganio, et al.
Pageof 2